Mucormycosis in ICU: A French Multicenter Cohort Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Mucormycosis
- Sponsor
- University Hospital, Grenoble
- Enrollment
- 74
- Locations
- 21
- Primary Endpoint
- Mortality at Day 28
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns.
ZygoRéa is a retrospective and multicentric French study aimed to evaluate survival of patients with mucormycosis admitted in ICU at day-28 after admission. This study will also try also to describe the epidemiology of patients admitted in ICU.
Detailed Description
Mucormycosis is an invasive fungal infection affecting patients with various clinical conditions especially patients with heavy immunosuppression or patients with trauma or extensive burns. The incidence of Mucormycosis is currently increasing reaching 7% of invasive fungal infections in some immunocompromised patients. Because of its aggressive nature, Mucormycosis is associated with poor survival and high morbidity ; mortality is estimated between 16% and 64% according to different retrospective studies. No study has ever evaluated prognosis of patients with mucormycosis admitted in intensive care units (ICU). ZygoRéa is a retrospective and multicentric French study aimed to evaluate survival of patients with mucormycosis admitted in ICU at day-28 after admission. This study will also try also to describe the epidemiology of patients admitted in ICU and to evaluate the prognosis of different subgroups of patients according to : * their clinical characteristics : demographic characteristics, clinical conditions and factors of immunosuppression * the characteristics of the fungal infection * the treatment strategy * the severity of the initial illness, evaluated by severity scores Twenty-one French ICU are currently including more than 45 patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •confirmed or suspected mucormycosis, based on international definition from EORTC/MSG
- •patient hospitalized in intensive care unit during the 2008-2016 period
- •Zygomycosis identification in at least 2 solids organs or identification in hemoculture
Exclusion Criteria
- •Age under 18 years old
- •Patient under the law
Outcomes
Primary Outcomes
Mortality at Day 28
Time Frame: up to 28 days
Mortality at Day 28 after ICU admission
Secondary Outcomes
- Length stay in ICU(up to 28 days)
- Length stay of hospitalization(up to 90 days)
- Mortality during the hospitalization(up to 90 days)
- Mortality at Day 90(up to 90 days)
- Mortality during the ICU stage(up to 28 days)
- Prognostic criteria(up to 28 days)